The types of EGFR mutations identified in plasma and tumour (EGFR activating, resistance‐conferring mutations in EGFR and other mutations) were identical for 11 of 12 (92%) mutations before treatment, and for 9 of 12 (75%) mutations after treatment (Appendix Fig S3 and Appendix Table S3). The gene discussed is EGFR; the disease is neoplasm.